Abstract
Two recent developments have served to refocus attention on the treatment of type 2 diabetes mellitus. First, the prevalence of the disease is increasing at an alarming rate, including in pediatric populations. Second has been the demonstration that intensive pharmacotherapy of the disease has a dramatically beneficial effect on its outcome. Control of hyperglycemia is not the only goal of therapy. In fact, the control of associated obesity, hypertension, and dyslipidemia may be as beneficial, if not more so, for longterm outcomes than is the regulation of glycemia. Furthermore, there well may be shared features in the pathogenesis of these and other comorbidities associated with the “metabolic syndrome,” making a separation of their treatment from those aimed at normoglycemia per se somewhat artificial. For example, most treatments that augment insulin action will lower serum triglycerides, other drugs may have direct cardiovascular effects that contribute to their overall beneficial effect, and certain antihypertensives can affect glucose homeostasis. However, this chapter will focus only on achieving normoglycemia. For further details on integrated diabetes care, such as surveillance and treatment of complications, or nutritional recommendations, the reader should consult more comprehensive sources such as the Clinical Practice Recommendations of the American Diabetes Association, published annually as a supplement to the journal Diabetes Care or available at their website (http://www.diabetes.org). The reader is also encour-aged to consult the many excellent texts and review articles available on specific aspects of treatment or agents mentioned below.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Horikawa Y, Oda N. Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26: 163–175.
Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610–630.
Lee Y, Hirose H, Ohneda M,. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA 1994;91:10, 878–10, 882.
McClain DA, Crook ED. Hexosamines and insulin resistance. Diabetes 1996; 45: 1003–1009.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
Bastyr EJ 3rd, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbAlc. IOEZ Study Group. Diabetes Care 2000; 23: 1236–1241.
Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998; 21: 1236–1239.
Donahue RP, Abbott RD, Reed DM, et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 198736: 689–692.
Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC- Norfolk). Br Med J 2001; 322: 15–18.
The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617–621.
Ashcroft SJ, Ashcroft FM. The sulfonylurea receptor. Biochim Biophys Acta 1992; 1175: 45–59.
Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996; 45: 223–241.
Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751–755.
Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998; 32: 1044–1052.
Kosaka K, Kuzuya T, Akanuma Y, et al. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980; 18: 23–28.
Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 197019: 789–830.
Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complic 2000; 14: 192–196.
Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with noninsulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426–1433.
Abraira C, Henderson WG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21: 574–579.
Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998; 98: 2227–2234.
Okumura S, Takeda N, Takami K, Yet al. Effects of troglitazone on dexamethasone-induced insulin resistance in rats. Metabolism 1998; 47: 351–354.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
McClain, D.A. (2003). Treatment of Type 2 Diabetes. In: Meikle, A.W. (eds) Endocrine Replacement Therapy in Clinical Practice. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-375-0_11
Download citation
DOI: https://doi.org/10.1007/978-1-59259-375-0_11
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-416-6
Online ISBN: 978-1-59259-375-0
eBook Packages: Springer Book Archive